CLARITY Extension Study

Summary

CLARITY Extension Study is a clinical trial^[1].

Key Facts

• CLARITY Extension Study is in the country of Australia^[2].
• CLARITY Extension Study is in the country of Austria^[3].
• CLARITY Extension Study is in the country of Belgium^[4].
• CLARITY Extension Study is in the country of Brazil^[5].
• CLARITY Extension Study is in the country of Bulgaria^[6].
• CLARITY Extension Study is in the country of Canada^[7].
• CLARITY Extension Study's instance of is recorded as clinical trial^[8].
• CLARITY Extension Study's start time is recorded as +2008-02-29T00:00:00Z^[9].
• CLARITY Extension Study's end time is recorded as +2011-12-31T00:00:00Z^[10].
• CLARITY Extension Study's sponsor is recorded as Merck KGaA^[11].
• CLARITY Extension Study's main subject is recorded as sclerosis^[12].
• CLARITY Extension Study's main subject is recorded as multiple sclerosis^[13].
• CLARITY Extension Study's number of participants is recorded as {'unit': '1', 'amount': '+867'}^[14].
• CLARITY Extension Study's title is recorded as A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)^[15].
• CLARITY Extension Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[16].
• CLARITY Extension Study's ClinicalTrials.gov ID is recorded as NCT00641537^[17].
• CLARITY Extension Study's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}^[18].
• CLARITY Extension Study's research intervention is recorded as cladribine^[19].
• CLARITY Extension Study's clinical trial phase is recorded as phase III clinical trial^[20].
• CLARITY Extension Study's research subject recruitment status is recorded as completed^[21].
• CLARITY Extension Study's study type is recorded as interventional study^[22].